LOGIN  |  REGISTER
Compass Therapeutics

908 Devices to Report Second Quarter 2024 Financial Results on August 6, 2024

July 23, 2024 | Last Trade: US$4.95 0.42 9.27

BOSTON / Jul 23, 2024 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, August 6, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event.

About 908 Devices

908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in forensics, bioprocessing, pharma/biopharma, life sciences research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page